# Management of multiple drug hypersensitivity in a child with very severe aplastic anemia: a case report and therapeutic challenge

**Authors:** Meihua Chen, Yi Deng, Pengyu Bin, Rong Gao, Nan Liao, Zhilin Zhou, Xin Huang, Jiaojiao Li, Jingsong Wang

PMC · DOI: 10.3389/fped.2026.1758240 · Frontiers in Pediatrics · 2026-02-17

## TL;DR

A child with severe anemia had allergic reactions to multiple drugs, requiring careful management and alternative treatments.

## Contribution

This case report highlights the occurrence of drug hypersensitivity in immunosuppressed patients and offers practical insights for treatment decisions.

## Key findings

- Severe hypersensitivity reactions occurred in a profoundly immunosuppressed pediatric patient.
- Alternative antimicrobial agents were successfully used after identifying culprit drugs with the Naranjo Algorithm.
- Switching from intravenous to oral levofloxacin was tolerated without adverse reactions.

## Abstract

This work presents the case of a pediatric patient with very severe aplastic anemia (VSAA) who developed severe hypersensitivity reactions sequentially to a carbapenem antibiotic and subsequently to intravenous levofloxacin during an episode of severe neutropenia with fever. This case illustrates that serious drug hypersensitivity reactions can occur even in the context of profound immunosuppression. In managing this complex scenario, the Naranjo Algorithm was utilized to identify the culprit medications. When adjusting the anti-infective regimen, we carefully balanced the benefits and risks, ultimately selecting appropriate alternative antimicrobial agents. Furthermore, the patient tolerated a switch from intravenous to oral levofloxacin without further adverse reactions, leading to a successful discharge. This case highlights the need for heightened vigilance among clinicians and pharmacists regarding the potential for severe drug allergies in immunocompromised, critically ill patients. This case also aims to share practical experience, hoping to provide a reference for the challenging decision-making process of anti-infective therapy in this vulnerable population.

## Linked entities

- **Chemicals:** carbapenem (PubChem CID 441133), levofloxacin (PubChem CID 149096)

## Full-text entities

- **Genes:** IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, MRGPRX2 (MAS related GPR family member X2) [NCBI Gene 117194] {aka MGRG3, MRGX2}, VIM (vimentin) [NCBI Gene 7431], BRAP (BRCA1 associated protein) [NCBI Gene 8315] {aka BRAP2, IMP, RNF52}, FCER1A (Fc epsilon receptor Ia) [NCBI Gene 2205] {aka FCE1A, FCERIA, FcERI}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** pruritic (MESH:C535817), rash (MESH:D005076), febrile (MESH:D000071072), bleeding (MESH:D006470), bleeding tendency (MESH:C536965), epistaxis (MESH:D004844), penicillin allergy (MESH:D008586), fever (MESH:D005334), pruritus (MESH:D011537), bone marrow failure (BMF) syndromes (MESH:D000080983), cutaneous adverse reactions (MESH:D013262), anaphylactic shock (MESH:D000707), shock (MESH:D012769), inflammatory (MESH:D007249), headache (MESH:D006261), deficiencies in platelets (MESH:D001791), critically ill (MESH:D016638), drug hypersensitivity syndrome (MESH:D063926), Thrombocytopenic Purpura (MESH:D011696), pancytopenia (MESH:D010198), tendon rupture (MESH:D012421), abdominal pain (MESH:D015746), neutropenic (MESH:D044504), edema (MESH:D004487), ecchymosis (MESH:D004438), febrile episode (MESH:C580065), bacterial infection (MESH:D001424), petechiae (MESH:D011693), SAA (MESH:D000741), liver function abnormalities (MESH:D056486), Enterobacteriaceae infections (MESH:D004756), allergic drug reaction (MESH:D004342), fungal (MESH:D009181), urticarial erythema (MESH:D004890), severe (MESH:D045169), ill (MESH:D002908), bloodstream infections (MESH:D018805), gingival bleeding (MESH:D005884), FN (MESH:D064147), anemia (MESH:D000740), rhinorrhea (MESH:D012818), symptoms (MESH:D012816), cytopenia (MESH:D006402), drop in blood pressure (MESH:D006973), immunodeficiency (MESH:D007153), neutropenia (MESH:D009503), death (MESH:D003643), subarachnoid hemorrhage (MESH:D013345), melena (MESH:D008551), drug eruption (MESH:D003875), Infection (MESH:D007239), gastrointestinal reactions (MESH:D005767), hypocellular marrow (MESH:D001855), cough (MESH:D003371), ototoxicity (MESH:D006311), Adverse Drug Reaction (MESH:D064420), dizziness (MESH:D004244)
- **Chemicals:** carbapenem (MESH:D015780), ceftazidime (MESH:D002442), Levofloxacin (MESH:D064704), Norepinephrine (MESH:D009638), vitamin C (MESH:D001205), voriconazole (MESH:D065819), glycyrrhizin (MESH:D019695), carbazochrome sodium sulfonate (MESH:C073338), histamine (MESH:D006632), aminoglycoside (MESH:D000617), loratadine (MESH:D017336), GM (MESH:C012990), beta-lactam antibiotics (MESH:D008997), epinephrine (MESH:D004837), imipenem (MESH:D015378), beta-lactam (MESH:D047090), creatinine (MESH:D003404), caspofungin (MESH:D000077336), calamine (-), Imipenem-cilastatin (MESH:D000077728), aztreonam (MESH:D001398), Cyclosporine (MESH:D016572), penicillin (MESH:D010406), fluoroquinolone (MESH:D024841), Amikacin (MESH:D000583), serine (MESH:D012694), linezolid (MESH:D000069349), oseltamivir (MESH:D053139)
- **Species:** Enterobacter (genus) [taxon 547], Escherichia coli (E. coli, species) [taxon 562], Alcaligenes (genus) [taxon 507], Pseudomonas aeruginosa (species) [taxon 287], Klebsiella pneumoniae (species) [taxon 573], Streptococcus mitis (species) [taxon 28037], Enterobacteriaceae (enterobacteria, family) [taxon 543], Acinetobacter baumannii (species) [taxon 470], Stenotrophomonas maltophilia (species) [taxon 40324], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953555/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953555/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953555/full.md

---
Source: https://tomesphere.com/paper/PMC12953555